Psyence Group's NASDAQ-Listed Associate, Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones

Initiated Phase IIb study of nature-derived psilocybin as a potential treatment for Adjustment Disorder in Palliative Care Expanded pipeline into Alcohol Use Disorder (AUD) and Substance Use Disorde… [+8997 chars]

Ads Links by Easy Branches
Play online games for free at games.easybranches.com

Guest Post Services www.easybranches.com/contribute
Psyence Group's NASDAQ-Listed Associate, Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones
Prediction of antimicrobial resistance of Klebsiella pneumoniae from genomic data through machine learning

Howard W. Robin Sells 14,881 Shares of Nektar Therapeutics (NASDAQ:NKTR) Stock
Laverock Therapeutics announces forthcoming investor, scientific and partnering conference schedule